Details for Patent: RE49826
✉ Email this page to a colleague
Which drugs does patent RE49826 protect, and when does it expire?
Patent RE49826 protects KERENDIA and is included in one NDA.
This patent has thirty-four patent family members in thirty countries.
Drugs Protected by US Patent RE49826
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer Hlthcare | KERENDIA | finerenone | TABLET;ORAL | 215341-001 | Jul 9, 2021 | RX | Yes | No | RE49826 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Bayer Hlthcare | KERENDIA | finerenone | TABLET;ORAL | 215341-002 | Jul 9, 2021 | RX | Yes | Yes | RE49826 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent RE49826
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 105774 | ⤷ Subscribe | |||
| Australia | 2016312904 | ⤷ Subscribe | |||
| Canada | 2995905 | ⤷ Subscribe | |||
| Chile | 2018000427 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
